|Bid||0.0000 x 2200|
|Ask||2.7000 x 1100|
|Day's Range||2.4417 - 2.6900|
|52 Week Range||1.0400 - 4.7800|
|Beta (5Y Monthly)||2.20|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Fortress Biotech (FBIO) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
Fortress Biotech has been struggling lately, but the selling pressure may be coming to an end soon.
Shares of Fortress Biotech (NASDAQ:FBIO), a biopharmaceutical company, were down by 22.5% as of 12:26 p.m. EDT on Monday, after dropping by as much as 28.3% earlier in the day. In December 2019, Avenue Therapeutics submitted an NDA for IV Tramadol for the management of acute pain in patients who require an opioid. The FDA had no complaints regarding the efficacy of the medicine.